Comparative Pharmacology
Head-to-head clinical analysis: CIN QUIN versus QUINIDINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIN QUIN versus QUINIDINE SULFATE.
CIN-QUIN vs QUINIDINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cin-Quin (quinidine) is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction velocity. It also has anticholinergic and alpha-adrenergic blocking properties.
Quinidine is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction. It also inhibits potassium channels, prolonging repolarization, and has vagolytic and negative inotropic effects.
Quinine sulfate 648 mg (two 324 mg capsules) orally every 8 hours for 7 days, in combination with doxycycline, tetracycline, or clindamycin.
300-600 mg orally every 6-8 hours; maximum 2-4 g/day. Extended-release: 300-600 mg every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 hours in healthy volunteers; prolonged to 8-12 hours in severe malaria or hepatic impairment.
Terminal elimination half-life is 6-8 hours in healthy adults; prolonged to 12-18 hours in heart failure, hepatic cirrhosis, or severe renal impairment (CrCl < 10 mL/min).
Primarily hepatic metabolism; renal excretion of unchanged drug <20%. Biliary/fecal excretion accounts for ~30% of total clearance.
Renal excretion of unchanged drug accounts for 10-20% of elimination; hepatic metabolism (hydroxylation and N-oxidation) accounts for 70-80%; about 5% excreted in feces via biliary elimination.
Category C
Category A/B
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)